Zhao, Wan-Hong
Wang, Bai-Yan
Chen, Li-Juan
Fu, Wei-Jun
Xu, Jie
Liu, Jie
Jin, Shi-Wei
Chen, Yin-Xia
Cao, Xing-Mei
Yang, Yun
Zhang, Yi-Lin
Wang, Fang-Xia
Zhang, Peng-Yu
Lei, Bo
Gu, Liu-Fang
Wang, Jian-Li
Zhang, Hui
Bai, Ju
Xu, Yan
Zhu, Han
Du, Juan
Jiang, Hua
Fan, Xiao-Hu
Li, Jian-Yong
Hou, Jian
Chen, Zhu
Zhang, Wang-Gang
Mi, Jian-Qing
Chen, Sai-Juan
He, Ai-Li
Clinical trials referenced in this document:
Documents that mention this clinical trial
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
https://doi.org/10.1186/s13045-022-01301-8
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
https://doi.org/10.1200/jco.2023.41.16_suppl.8010
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Funding for this research was provided by:
Key Research and Development Plan of ShaanXi Province (2018SF-002, 2017ZDXM-SF-25-6 (Approval No. 2018ZDXM-SF-039))
National Natural Science Foundation of China (81970189)
Article History
Received: 11 March 2022
Accepted: 3 June 2022
First Online: 6 July 2022
Declarations
:
: This study was performed in accordance with the Declaration of Helsinki and was approved by the institutional independent ethics committee.
: Not applicable.
: X-HF is employed by Legend Biotech. All other authors declare that they have no competing interests.